Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
- Total Revenues of $480 million for the Fourth Quarter of 2023, $1,830 million for the Fiscal Year 2023 Cabozantinib Franchise Achieved $1,629 million in U.S. Net Product Revenues for the Fiscal Year 2023, including $429 million for the Fourth Quarter of 2023 GAAP Diluted EPS of $0.27 for the Fourth Quarter o.
- Total Revenues of $480 million for the Fourth Quarter of 2023, $1,830 million for the Fiscal Year 2023 -
- Cabozantinib Franchise Achieved $1,629 million in U.S. Net Product Revenues for the.
Exelixis, Inc. today reported financial results for the fourth quarter and fiscal year of 2023, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones..
– Cabozantinib franchise achieves approximately $1.630 billion in preliminary U.S. net product revenues for fiscal year 2023 –
– Fiscal year 2024 net product revenues guidance of $1,650.